SCHEMBL3476327

SCHEMBL3476327

NNc1cc2ccccc2[nH]1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AOC3 Q16853 2/20 0.54
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 4/20 0.50
GAA P10253 1/20 0.50
MAPK1 P28482 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.48
CA2 P00918 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MAPT P10636 3/20 0.44
HPGD P15428 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
CASP3 P42574 1/20 0.44
KMT2A Q03164 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30287355 1.00 AOC3 (0.54) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL27075383 0.82 AOC3 (0.52) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL28488611 0.80 AOC3 (0.50) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL10826335 0.78 FLT3 (0.48) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL29636187 0.78 AOC3 (0.48) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL3191163 0.78 AOC3 (0.48) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL31232953 0.78 FLT3 (0.48) AOC3KDM4EALDH1A1GAAMAPK1
Iodide SCHEMBL28673444 0.77 AOC3 (0.47) AOC3KDM4EALDH1A1GAAMAPK1
Phosphine SCHEMBL28563766 0.77 AOC3 (0.47) AOC3KDM4EALDH1A1GAAMAPK1
SCHEMBL29563733 0.75 MAPT (0.59) AOC3KDM4EALDH1A1GAANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109071634-A Antibody coupling matter and its preparation and application R.P.谢勒技术有限责任公司 2018-12-21 CN claimed
WO-2018169953-A1 ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING THE SAME R.P. SCHERER TECHNOLOGIES, LLC (US) 2018-09-20 WO claimed
WO-2017189432-A1 ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING THE SAME R.P. SCHERER TECHNOLOGIES, LLC (US) 2017-11-02 WO claimed
US-20170306300-A1 ANTIBODY CONJUGATES AND METHODS OF MAKING AND USING THE SAME ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2017-10-26 US claimed
US-20250381290-A1 Antibody Conjugates and Methods of Making and Using the Same SCHERER TECHNOLOGIES LLC R P (US) 2025-12-18 US disclosed
EP-4592275-A2 HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE Redwood Bioscience, Inc. (US) 2025-07-30 EP disclosed
EP-3074010-B1 HYDRAZINYL-PYRROLO COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE REDWOOD BIOSCIENCE INC (US) 2025-05-14 EP disclosed
US-12296021-B2 Antibody conjugates and methods of making and using the same R.P. SCHERER TECHNOLOGIES, LLC (US) 2025-05-13 US disclosed
WO-2025064427-A1 DUAL-PAYLOAD ANTIBODY-DRUG CONJUGATES AND USES THEREOF R.P. SCHERER TECHNOLOGIES, LLC (US) 2025-03-27 WO disclosed
US-12215080-B2 Hydrazinyl-pyrrolo compounds and methods for producing a conjugate REDWOOD BIOSCIENCE, INC. (US) 2025-02-04 US disclosed
US-12076411-B2 Anti-HER2 antibody-maytansine conjugates and methods of use thereof REDWOOD BIOSCIENCE, INC. (US) 2024-09-03 US disclosed
US-20240101975-A1 Antibody Conjugates and Methods of Making and Using the Same ARES CAPITAL CORPORATION, AS COLLATERAL AGENT 2024-03-28 US disclosed
WO-2014078566-A1 HYDRAZINYL-INDOLE COMPOUNDS AND CONJUGATES REDWOOD BIOSCIENCE, INC. (US) 2014-05-22 WO disclosed
WO-2014078566-A1 HYDRAZINYL-INDOLE COMPOUNDS AND CONJUGATES REDWOOD BIOSCIENCE, INC. (US) 2014-05-22 WO disclosed
US-20140141025-A1 HYDRAZINYL-INDOLE COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE REDWOOD BIOSCIENCE, INC. (US) 2014-05-22 US disclosed
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors MERCK SHARP & DOHME CORP. 2010-07-15 US disclosed
EP-1898927-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS Merck & Co., Inc. (US) 2008-03-19 EP disclosed
WO-2007002481-A2 NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MERCK & CO., INC. (US) 2007-01-04 WO disclosed
US-4600721-A ENZYME INHIBITORS, ANTIINFLAMMATORY, ANTIPYRETICS, BENZOTHIAZOLE AND BENZOXAZOLE HYDRAZINES LUDWIG HEUMANN & CO., GMBH (DE) 1986-07-15 US disclosed
US-4476137-A ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1984-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179122-A1 Non-Nucleoside Reverse Transcriptase Inhibitors RNGTT, RTF1, POLR1E AOC3 3700/4885KDM4E 1660/4885ALDH1A1 1178/4885
US-20140141025-A1 HYDRAZINYL-INDOLE COMPOUNDS AND METHODS FOR PRODUCING A CONJUGATE HNMT, AANAT, INMT AOC3 2022/4885KDM4E 3088/4885ALDH1A1 1454/4885
US-20250381290-A1 Antibody Conjugates and Methods of Making and Using the Same PFAS, FGR, FGB AOC3 1544/4885KDM4E 903/4885ALDH1A1 1880/4885
US-12215080-B2 Hydrazinyl-pyrrolo compounds and methods for producing a conjugate DNPEP, QPCT, PDS5A AOC3 2218/4885KDM4E 2215/4885ALDH1A1 1538/4885
US-12076411-B2 Anti-HER2 antibody-maytansine conjugates and methods of use thereof ERBB2, EGFR, ERBB3 AOC3 3034/4885KDM4E 2372/4885ALDH1A1 1950/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.